This cohort study uses propensity score matching to assess the effectiveness of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) for primary prevention of major adverse cardiovascular and cerebrovascular events in patients with monoclonal gammopathy of undetermined significance and diabetes. Here, GLP1R is linked to diabetes mellitus.